Katherine Randolph

Sr. Director, Clinical Operations at CalciMedica

Role: Sr Director, Clinical Operations at Calcimedica
Location: San Diego, CA, US
LinkedIn followers: 500 followers

Healthcare & Human ServicesView LinkedIn profile

About Katherine Randolph

Senior Director of Clinical Operations driving programs from start-up through NDA…

Experience

Sr Director, Clinical Operations
Calcimedica
Jan 2020 — Present · San Diego, CA, US
Align clinical operations strategy with company goals to drive long-term success. • Develop and execute strategic plans for efficient clinical trial delivery. • Oversee vendor selection and management to ensure optimal performance across programs. • Forecast and monitor clinical trial finances for fiscal efficiency and alignment.Therapeutic Areas: COVID-19, acute pancreatitis, acute kidney injury

Education

San Diego State University
Bachelor's degree
San Diego State University
Master's degree

Skills

Ich-Gcp
Psoriasis
Project Planning
Clinical Development
CRO
Drug Development
Gcp
Sarcoma
Pharmaceutical Industry
Interventional Cardiol
Cardiology
Budgets
Dermatology
Acute Myeloid Leukemia
Neurology
Edc
Ctms
Solid Tumor
Clinical Operations
Management
Clinical Monitoring
Gastroenterology
Line Management
Trial Management
Clinical Trials
Cross-Functional Team Leadership
Breast Cancer
Oncology

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
k••••••••@calcimedica.com
Personal email
•••••@•••••.com
Direct dial
+16•••••••06

Unlock verified contacts

Free to start · No credit card required

Current company

Calcimedica

Biotechnology · 18 employees · Founded 2007 · La Jolla, California, United States

CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica\'s proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica\'s lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials and been well-tolerated in over 350 critically ill patients dosed. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04••••66) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and for a Phase 2 trial (called CARDEA – NCT04••••14) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE –NCT06••••97) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF).

calcimedica.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.